Pancreatic Cancer Research

ResearcherUniversity of VeronaActive in the last 2 years

Domenico Tamburrino

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1435-3651; OpenAlex author ID A5059355722. Sources: OpenAlex.

Their work

Papers
35 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
104
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: 2 papers · 2015: none · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 2 papers · 2020: 4 papers · 2021: 5 papers · 2022: 1 paper · 2023: 3 papers · 2024: 6 papers · 2025: 4 papers · 2026: 5 papers

Papers 35

  1. Neoadjuvant Chemotherapy With or Without Radiotherapy in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2026.3716↗
  2. Preoperative mFOLFIRINOX versus PAXG for stage I-III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the … Co-author DOI 10.1016/s0140-6736(25)01685-x↗
  3. Actual Five-year Survival After Neoadjuvant Therapy and Resection for Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000007214↗
  4. Risk Factors for Early Disease-Related Mortality Among Patients with Localized Pancreatic Cancer Resected After Neoadjuvant Treatment. Co-author DOI 10.1245/s10434-026-19218-8↗
  5. ASO Visual Abstract: Risk Factors for Early Disease-Related Mortality Among Patients with Localized Pancreatic Cancer Resected After Neoadjuvant Treatment. Co-author DOI 10.1245/s10434-026-19370-1↗
  6. Pancreatic cancer and long survivors: a survey of Italian society of oncological surgery (SICO). Co-author DOI 10.1007/s13304-024-02039-3↗
  7. Diagnostic delay at diagnosis and time-to-treatment influence overall survival of pancreatic cancer patients. Co-author DOI 10.1016/j.dld.2025.03.009↗
  8. Anatomically resectable versus biologically borderline resectable pancreatic cancer definition: refining the border beyond anatomical criteria and biological a… Co-author DOI 10.1093/bjsopen/zraf033↗
  9. Prognostic Validation of Perineural Invasion Severity Score in Pancreatic Cancer: A Prospective Study. Co-author DOI 10.1097/sla.0000000000006920↗
  10. REDISCOVER guidelines for borderline-resectable and locally advanced pancreatic cancer: management algorithm, unanswered questions, and future perspectives. Co-author DOI 10.1007/s13304-024-01860-0↗
  11. Hypofractionated radiotherapy concomitant to capecitabine after induction chemotherapy for advanced pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ctro.2024.100778↗
  12. Exploring the optimal therapeutic management of stage ypIA pancreatic ductal adenocarcinoma patients in the era of primary chemotherapy. Co-author DOI 10.1016/j.dld.2023.07.006↗
  13. Pathologic complete response following neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma: Impact on survival and recurrence. Co-author DOI 10.1016/j.surg.2024.07.026↗
  14. REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006248↗
  15. Very Early Recurrence After Curative Resection for Pancreatic Ductal Adenocarcinoma: Proof of Concept for a "Biological R2 Definition". Co-author DOI 10.1245/s10434-024-15105-2↗
  16. Surgical Planning for "Borderline Resectable" and "Locally Advanced" Pancreatic Cancer During Open Pancreatic Resection. Co-author DOI 10.1007/s11605-023-05848-w↗
  17. The role of biliary events in treatment and survival of patients with advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.dld.2023.04.015↗
  18. Pancreatectomy with venous vascular resection for pancreatic cancer: Impact of types of vein resection on timing and pattern of recurrence. Co-author DOI 10.1016/j.ejso.2023.03.229↗
  19. Feasibility of therapeutic endoscopic ultrasound in the bridge-to-surgery scenario: The example of pancreatic adenocarcinoma. First author DOI 10.3748/wjg.v28.i10.976↗
  20. Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patients. Co-author DOI 10.1007/s00280-020-04190-1↗
  21. Does chronic consumption of angiotensin-converting enzyme inhibitors affect survival after surgical resection of pancreatic ductal adenocarcinoma? Co-author DOI 10.1016/j.dld.2021.04.027↗
  22. Recurrence after surgical resection of pancreatic cancer: the importance of postoperative complications beyond tumor biology. Co-author DOI 10.1016/j.hpb.2021.04.004↗
  23. Long-Term Survivors after Upfront Resection for Pancreatic Ductal Adenocarcinoma: An Actual 5-Year Analysis of Disease-Specific and Post-Recurrence Survival. Co-author DOI 10.1245/s10434-021-10401-7↗
  24. Prediction of Early Distant Recurrence in Upfront Resectable Pancreatic Adenocarcinoma: A Multidisciplinary, Machine Learning-Based Approach. Co-author DOI 10.3390/cancers13194938↗
  25. Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00280-020-04047-7↗
  26. Statin use improves survival in patients with pancreatic ductal adenocarcinoma: A meta-analysis. Co-author DOI 10.1016/j.dld.2020.01.008↗
  27. Respect - A multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer. Co-author DOI 10.1016/j.pan.2020.06.012↗
  28. Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is f… Co-author DOI 10.1016/j.suronc.2020.08.031↗
  29. Risk and Predictors of Postoperative Morbidity and Mortality After Pancreaticoduodenectomy for Pancreatic Neuroendocrine Neoplasms: A Comparative Study With Pa… First author DOI 10.1097/mpa.0000000000001273↗
  30. Postoperative Outcomes and Functional Recovery After Preoperative Combination Chemotherapy for Pancreatic Cancer: A Propensity Score-Matched Study. Co-author DOI 10.3389/fonc.2019.01299↗
  31. Systematic review and meta-analysis of prognostic role of splenic vessels infiltration in resectable pancreatic cancer. Co-author DOI 10.1016/j.ejso.2017.10.217↗
  32. [Pancreatic cancer]. First author DOI 10.1701/2296.24698↗
  33. The role of (18)fluoro-deoxyglucose positron emission tomography/computed tomography in resectable pancreatic cancer. Co-author DOI 10.1016/j.dld.2014.03.011↗
  34. Selection criteria in resectable pancreatic cancer: a biological and morphological approach. Co-author DOI 10.3748/wjg.v20.i32.11210↗
  35. Splenic artery invasion in pancreatic adenocarcinoma of the body and tail: a novel prognostic parameter for patient selection. Co-author DOI 10.1245/s10434-011-1769-1↗

Closest collaborators

The 25 strongest of 104 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Massimo Falconi · 29 shared papers, 2011–2026 · strength 4.39
  2. Stefano Crippa · 22 shared papers, 2011–2026 · strength 3.45
  3. Stefano Partelli · 22 shared papers, 2011–2026 · strength 3.37
  4. Giulio Belfiori · 19 shared papers, 2019–2026 · strength 3.37
  5. Michele Reni · 18 shared papers, 2018–2026 · strength 3.05
  6. Giulia Gasparini · 11 shared papers, 2021–2026 · strength 2.04
  7. Marco Schiavo Lena · 9 shared papers, 2024–2026 · strength 1.88
  8. Federico De Stefano · 9 shared papers, 2023–2026 · strength 1.85
  9. Diego Palumbo · 8 shared papers, 2021–2026 · strength 1.57
  10. Nicolò Pecorelli · 8 shared papers, 2019–2026 · strength 1.52
  11. Marina Macchini · 8 shared papers, 2020–2026 · strength 1.34
  12. Giulia Orsi · 8 shared papers, 2020–2026 · strength 1.34
  13. Francesco DE COBELLI · 6 shared papers, 2021–2026 · strength 1.17
  14. Gabriele Capurso · 6 shared papers, 2020–2026 · strength 0.99
  15. Paolo Giorgio Arcidiacono · 6 shared papers, 2020–2026 · strength 0.94
  16. Paolo Riccardo Camisa · 4 shared papers, 2024–2026 · strength 0.85
  17. Giuseppe Malleo · 5 shared papers, 2020–2026 · strength 0.83
  18. Gianpaolo Balzano · 5 shared papers, 2019–2026 · strength 0.79
  19. Roberto Salvia · 5 shared papers, 2020–2026 · strength 0.77
  20. Gabriella Lionetto Lionetto · 3 shared papers, 2025–2026 · strength 0.61
  21. Claudio Doglioni · 3 shared papers, 2021–2025 · strength 0.52
  22. Lívia Archibugi · 3 shared papers, 2020–2025 · strength 0.46
  23. Fabio Casciani · 2 shared papers, 2026 · strength 0.46
  24. Claudio Luchini · 2 shared papers, 2026 · strength 0.46
  25. Theodore Sunki Hong · 2 shared papers, 2026 · strength 0.42

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.